BUZZ-Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> climbs on promising cancer drug data** Shares of drug developer Silexion Therapeutics SLXN.O rise 11% to $3.75 premarket
** Says its experimental cancer drug, SIL204, showed strong activity in lab tests, targeting a wide range of KRAS mutations linked to aggressive cancers
** Reports inhibition rates between 83.5% and 99.7% in 11 human cancer cell lines, including its first data in gastric cancer and expanded results in colorectal cancer
** SIL204 also showed high potency against the G12R mutation, which affects about 17% of pancreatic cancer patients
** Plans to start mid-to-late stage trials in the first half of 2026
** As of last close, stock down 88% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.